Case Reports in Pediatrics
Volume 2018 (2018), Article ID 1543934, 3 pages
https://doi.org/10.1155/2018/1543934

Case Report

Stenotrophomonas maltophilia Meningitis in a Term Healthy Neonate: A Case Report and Literature Review

Judy Ibrahim,¹ Nadia Hamwi,¹ Hala Rabei,¹ Mohamed Abdelghafar,¹ Zahraa Al-Dulaimi,² and Hossam Al Tatari³

¹Department of Academic Affairs, Tawam Hospital, Al Ain, UAE
²Dubai Medical College, Dubai, UAE
³Pediatrics Infectious Diseases Department, Tawam Hospital, Al Ain, UAE

Correspondence should be addressed to Judy Ibrahim; drjudyibrahim@gmail.com

Received 12 February 2018; Revised 11 April 2018; Accepted 16 April 2018; Published 13 June 2018

Academic Editor: Bernhard Resch

Copyright © 2018 Judy Ibrahim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Stenotrophomonas maltophilia is an environmental bacterium of growing concern due to its multidrug resistance and pathogenic potential. It is considered an opportunistic pathogen of nosocomial origin most of the time, targeting a specific patients' population. We describe a case of a previously healthy full-term neonate who was found to have S. maltophilia meningitis and was successfully treated with a combination of Trimethoprim-Sulfamethoxazole and Ciprofloxacin.

1. Introduction

S. maltophilia was first described by Hugh and Ryschenkow in 1961 [1] as a Gram-negative, glucose nonfermentative aerobic rod bacteria. It was previously known as Pseudomonas maltophilia and Xanthomonas maltophilia. S. maltophilia is known as a low-virulence commensal organism that was typically isolated within hospitals and health-care facilities. Therefore, it is usually believed to be an opportunistic nosocomial pathogen. However, community-acquired S. maltophilia infections have been reported. S. maltophilia is now of rising importance since it is a multidrug resistant organism that is associated with high morbidity and mortality. It is known to cause a wide spectrum of serious infections, including bacteremia, endocarditis, ocular infections, urinary tract infections, skin and soft tissue infections, pyomyositis, sepsis, and meningitis [2]. S. maltophilia meningitis in pediatrics is very rare with only very few cases reported since 1977.

2. Case Presentation

This was a 13 days old baby boy, who was born via spontaneous vaginal delivery at term in our tertiary care hospital without any postnatal complications. He was discharged 24 hours after delivery. He was brought back to our ER with left eye purulent discharge, which was noticed since birth, and swelling of his left upper eyelid of 2 days duration.

There was no associated fever or history of decreased level of activity or feeding. There was no history of rashes or seizures.

The pregnancy course was remarkable only for gestational diabetes and the fact that the mother had a history of vaginal discharges, which was treated as vaginal candidiasis during the last trimester. Group B streprococcus screening on the 37th week of gestation was negative. Similarly, HIV and hepatitis B serology were negative one day prior to delivery. There was no maternal history of genital lesions, vesicles, or ulcers.

Examination was normal apart from the purulent eye discharge & swelling of the left eye upper eyelid. The eye secretions were yellowish sticky, copious, and profound. Fontanelles were soft & primitive reflexes were present and normal.

Due to suspicion of gonococcal ophthalmia neonatorum, a full septic workup was obtained including CBC, blood culture, urine analysis and culture, CSF analysis and culture, and left eye swab for culture and Chlamydia antigen (Table 1). He was subsequently started on meningitis dose of Cefotaxime, in addition to Gentamycin ophthalmic drops while waiting for the previous cultures' results. Azithromycin was added as well to cover the possibility of an associated chlamydial infection.

Table 1: Laboratory investigations performed at the time of admission.

Test
Results

Blood

    WBC
17.1 × 10 ^ 9/L

        PMNs (%)
6.15 × 10 ^ 9/L (36%)

        Lymphocytes (%)
8.03 × 10 ^ 9/L (47%), atypical 4%

        Monocytes (%)
1.54 × 10 ^ 9/L (9%)

    Hb (Hct)
177 g/L (0.50)

    Platelets
392 x 10 ^ 9/L

Urine

    WBCs
<5

    RBCs
<1

    Nitrite/Leuk. Est.
-/-

CSF

    WBC
14 cells/mm³ (65% lymphocytes, 35% monocytes)

    RBCs
101 cells/mm³

    Color, clarity
Colorless, clear

WBC: white blood counts, PMNs: polymorph nuclear cells, Hb: hemoglobin, Hct: hematocrit, Leuk. Est.: leukocyte esterase, and CSF: cerebrospinal fluid.

The eye swab culture revealed Neisseria gonorrhea, which was sensitive to Cefotaxime, so the antibiotic was continued while waiting for the results of the CSF culture.

Blood and urine cultures were negative. The CSF culture revealed Gram-negative rods after one day, which was identified as S. maltophilia on day 5 of admission. The organism was sensitive to Trimethoprim-Sulfamethoxazole (TMP-SMX).

Once the diagnosis of S. maltophilia meningitis was identified, Cefotaxime was stopped and the baby was started on TMP-SMX and Ciprofloxacin. Since there are no clear guidelines on how to treat S. maltophilia meningitis in neonates, we extrapolated our management plan from that of other Gram-negative meningitis. Therefore, CSF was repeated at 2 days of antibiotics to confirm sterility. Because S. maltophilia meningitis is very rare and there are no clear guidelines on the duration of therapy, the treating team decided to repeat CSF studies one more time toward the end of the third week of antibiotics. The last CSF studies were completely normal, and the culture was negative.

The baby’s head circumference was measured daily during the hospital stay and remained normal. Cranial ultrasound scan was normal.

The little boy recovered from the infection uneventfully and a follow-up visit of the baby 1 week after discharge was reassuring. His parents received treatment for gonorrhea and they were screened for other sexually transmitted diseases.

3. Discussion

Populations at risk for S. maltophilia meningitis are typically immunocompromised patients, those who had neurosurgical procedures, preterm babies, and patients in need of prolonged hospitalization [2]. To our knowledge, only seven reports of S. maltophilia meningitis have been published to date, all of who had at least one of the above risk factors (Table 2). Our patient seems to be unique since he had none of the previous risk factors.

Table 2: Reported pediatric cases of S. maltophilia meningitis.

Case
Age, gender
Risk factor
Origin
Treatment
Outcome

Denis et al. [3]
8 mo, M
13 mo, F
None
None
Community
Ampicillin + Colistin
Chloramphenicol + Sulphadoxine
Died
Recovered

Sarvamangala Devi et al. [4]
7 days, M
Premature
Community
None
Died

Wen-Tsung et al. [5]
4 days, F
Premature
Nosocomial
Ciprofloxacin
Recovered

Rojas et al. [6]
12 days, M
Premature, EVD, ICH
Nosocomial
TMP-SMX and Ciprofloxacin
Recovered

Sood et al. [7]
6 months, M
Premature, VP shunt insertion
Nosocomial
Amikacin and TMP-SMX
Recovered

Correia et al. [8]
4 years, M
Premature, VP shunt, EVD
Nosocomial
TMP-SMX, Ceftazidime, and Levofloxacin
Recovered

Tandel et al. [9]
5 months, M
EVD
Nosocomial
TMP-SMX
Recovered

VP: ventricular-peritoneal, EVD: external ventricular device, and ICH: intracerebral hemorrhage.

S. maltophilia is well known to be resistant to several antibiotics that are commonly used empirically for nosocomial infections. Mechanisms of resistance include production of beta-lactamase, efflux, biofilm formation, and aminoglycoside-modifying enzyme activity [7]. Another alarming feature of this pathogen is the significant heterogeneity among its isolates with high rate of genetic mutation [10].

The treatment of choice for S. maltophilia is Trimethoprim-Sulfamethoxazole (TMP-TMX), based on in vitro susceptibility tests and good clinical response reported in the past. Ciprofloxacin, Ceftazedime, and Ticarcillin/Clavulanate as monotherapy or in combination with other agents have been used with success. The optimal duration of therapy for S. maltophilia meningitis has not been well studied. We believe it should be similar to the duration used when treating other Gram-negative meningitis (i.e., at least three weeks). Likewise, we recommend obtaining CSF studies 48 hours after starting antibiotics to confirm sterility, and towards the end of the therapy to confirm normalization of all the CSF indices.

4. Conclusion

Stenotrophomonas maltophilia has received rising attention in the recent years since it is known as an evolving multidrug resistant organism. It is commonly identified as a cause of nosocomial infections; however, community-acquired infections are increasingly being reported. Although S. maltophilia meningitis continues to be rare in pediatric population, clinicians should be aware of it as a possible causative organism of meningitis, even in the absence of its known risk factors. We believe there is a lot yet to be learned about S. maltophilia and its associated clinical spectrum and appropriate duration of therapy for each condition.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

R. Hugh and E. Ryschenkow, “Pseudomonas maltophilia, an Alcaligenes-like species,” Journal of General Microbiology, vol. 26, no. 1, pp. 123–132, 1961.

A. A. Anthony, A. S. Thor, and I. O. Anthony, “Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy,” Frontiers in Microbiology, vol. 8, 2017.

F. Denis, A. Sow, M. David, J. P. Chiron, A. Samb, and M. I. Diop, “Study of 2 cases of Pseudomonas maltophilia meningitis observed in Senegal (in French),” Bulletin De La Societe Medicale d’Afrique Noire De Langue Francaise, vol. 22, no. 2, pp. 135–139, 1977.

J. N. Sarvamangala Devi, A. Venkatesh, and P. G. Shivananda, “Neonatal infections due to Pseudomonas maltophilia,” Indian Pedaitrics, vol. 21, no. 1, pp. 72–74, 1984.

L. Wen-Tsung, W. Chih-Chien, L. Chuen-Ming, and C. Mong-Ling, “Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant,” European Journal of Pediatrics, vol. 161, no. 12, pp. 680–682, 2002.

P. Rojas, E. Garcia, G. M. Calderón, F. Ferreira, and M. Rosso, “Successful treatment of Stenotrophomonas maltophilia meningitis in a preterm baby boy: a case report,” Journal of Medical Case Reports, vol. 3, no. 1, p. 7389, 2009.

S. Sood, V. K. Vaid, and H. Bhartiya, “Meningitis due to Stenotrophomonas maltophilia after a neurosurgical procedure,” Journal of Clinical and Diagnostic Research, vol. 7, no. 8, pp. 1696-1697, 2013.

C. R. Correia, S. T. Ferreira, and P. Nunes, “Stenotrophomonas maltophilia: rare cause of meningitis,” Pediatrics International, vol. 56, no. 4, pp. 21-22, 2014.

K. U. Tandel, P. Bhatt, and P. Ranjan, “Stenotrophomonas maltophilia meningitis in a pediatric patient following neurosurgery,” Reviews in Medical Microbiology, vol. 26, no. 4, pp. 168–170, 2015.

J. S. Brooke, “Stenotrophomonas maltophilia: an emerging global opportunistic pathogen,” Clinical Microbiology Reviews, vol. 25, no. 1, pp. 2–41, 2012.